Parallel Advisors’s Kymera Therapeutics KYMR Stock Holding History

Parallel Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.41K	Sell	21 -6	-22%	-$516	﹤0.01%	3476
2026 Q1	$2.25K	Buy	27 +7	+35%	+$554	﹤0.01%	3333
2025 Q4	$1.56K	Hold	20	–	–	﹤0.01%	3202
2025 Q3	$1.13K	Hold	20	–	–	﹤0.01%	3192
2025 Q2	$873	Sell	20 -8	-29%	-$275	﹤0.01%	3222
2025 Q1	$766	Buy	28 +15	+115%	+$547	﹤0.01%	3171
2024 Q4	$523	Sell	13 -8	-38%	-$361	﹤0.01%	3217
2024 Q3	$994	Buy	21 +13	+163%	+$574	﹤0.01%	3038
2024 Q2	$239	Hold	8	–	–	﹤0.01%	3186
2024 Q1	$322	Hold	8	–	–	﹤0.01%	3103
2023 Q4	$204	Buy	+8	New	+$143	﹤0.01%	3166
2022 Q1	–	Sell	-21	Closed	-$1K	–	3126
2021 Q4	$1K	Sell	21 -650	-97%	-$37.9K	﹤0.01%	2895
2021 Q3	$39K	Buy	671 +650	+3,095%	+$37.7K	﹤0.01%	1393
2021 Q2	$1K	Buy	+21	New	+$912	﹤0.01%	2760

Other funds holding KYMR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Parallel Advisors's KYMR Position: Q2 2026 in Review

Parallel Advisors reduced its Kymera Therapeutics (KYMR) stake by 22% in Q2 2026, selling an estimated $516 and leaving 21 shares worth $2.41K. The position accounts for ﹤0.01% of the portfolio, ranked #3476.

Parallel Advisors first reported a position in KYMR in Q2 2021 and has held it in 14 quarters since. The position peaked at $39K in Q3 2021. 93 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Parallel Advisors held 21 shares of Kymera Therapeutics worth $2.41K as of Q2 2026.
Parallel Advisors sold 6 Kymera Therapeutics shares in Q2 2026, an estimated $516.
Kymera Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3476 holding.
Parallel Advisors first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 14 quarters since.
Parallel Advisors's Kymera Therapeutics position peaked at $39K in Q3 2021.
93 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.